Skip to main content
Equibles
NNVC logo

NNVC · Nanoviricides, Inc.

Track NNVC — free

Use NNVC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NNVC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.33 +0.02 (+1.53%) At close · Aug 21
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management believes that the Company’s cash and cash equivalents balance of approximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”
View the 10-Q filed May 15, 2026
Market Cap
$28.79M
Shares
21.65M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.33 Open$1.33 Day$1.31–1.39 52W close$0.85–2.03 Avg vol 30d353K Short int597K · 2.8% float · 1.6d Short vol50% DataJan 2020–Aug 2026 Filing10-Q · May 15

Up next

FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 15, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg −9%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 41%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +37%
trailing
YTD return +18%
this year
Relative strength +26%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.76% of float · ▼ -18.5% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
49 holders — near 3-yr high, broad support
Squeeze score 41
elevated · 0–100
Fundamentals
Weak
EPS growth +10%
Y/Y
Free cash flow $-8.5M
Balance sheet $8.6M
net debt
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −58%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
41% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.76% of float · ▼ -18.5% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
49 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 41% Range high $2
vs 200-day avg +3% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NNVC
Nanoviricides, Inc.
this stock
$28.79M +17.7% — — 2.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
49
% held
11.5%
Net QoQ
+560.0K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
596.9K
Days to cover
1.6d
Change
-135.6K sh
View
Short Volume
Short vol %
50%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$1.9K
As of
Jul 21, 2026
View
Off-Exchange
Off-exchange %
49.1%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Kelly Loeffler
Amount
$1.0K–$15.0K
Traded
Apr 7, 2020
View
Financials
Financials
Net income (FY)
$-9.5M
EPS diluted
$-0.63
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 30, 2026
This year
6
View
Exempt Offerings
Offering
$6.0M
Filed
Feb 25, 2026
View

Performance

5D 20D 120D MTD YTD
NNVC -3.6% -10.1% +37.1% -12.5% +17.7%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY -2.3% -13.8% +25.6% -15.0% +5.4%
Key facts CIK 1379006 CUSIP 630087302 13F (30d) 45 filings 45 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)